KNOWLEDGE BANK

Interviews

From Single-Cell to Spatial Intelligence: The Next Era of Precision Medicine

Founder & Strategic Advisor, Genomics Consult
Dr Elsa Molina is a PhDtrained biologist and strategic scientific leader specializing in singlecell genomics spatial omics and nextgeneration sequencing technologies With over eight years of experience at the Salk Institute and University of California San Diego her background spans Europe Australia and North America Dr Molina is Founder Strategic Advisor at Genomics Consult advising on translati...

Articles

Single Domain Antibody

Monoclonal and polyclonal antibodies Abs are wellcorroborated tools adopted in basic biomedical research and innovative key components of numerous therapeutic platforms today on the market The vast majority of the Abs are obtained from easily accessible laboratory animals such as mice hamsters and rabbits and consist of two heavy and two light chains

Research Insights

DNA supercoiling differences in bacteria result from disparate DNA gyrase activation by polyamines

DNA supercoiling is essential for all living cells because it controls all processes involving DNA In bacteria global DNA supercoiling results from the opposing activities of topoisomerase I which relaxes DNA and DNA gyrase which compacts DNA These enzymes are widely conserved sharing amino acid identity between the closely related

Case Studies

<sup>14</sup>C microtracer+Accelerator Mass Spectrometry - Xceleron Case Studies

Introduction Xceleron is a world leader in the use of Accelerator Mass Spectrometry AMS analytical technology in pharmaceutical food technology crop protection and biobased product applications Our primary business is in pharmaceutical research and development Since we have been helping to design preclinical and clinical investigations around the

Techno Trends

Biogen Develops QALSODY®, the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen has developed QALSODY a groundbreaking therapy for adults with amyotrophic lateral sclerosis linked to a mutation in the superoxide dismutase gene

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Machine Learning for New Drugs

Sneha Rai

Sneha Rai completed her Ph.D. from Computational and Structural Biology Lab., Department of Biological Sciences and Engineering at Netaji Subhas Institute of Technology (DU). She did masters in Bioinformatics from Banaras Hindu University and holds six years of bioinformatics research experience. Her area of interest includes structural bioinformatics, systems biology, protein/gene network analysis, data mining, computer aided drug designing, computational genomics, NGS data analysis, variant analysis and their clinical interpretation.

 

Venugopal Bhatia

Venugopal Bhatia graduated from NSIT in 2019 with a B.E. in Biotechnology. During his undergraduate studies he was involved as an undergraduate researcher at the Computational and Structural Biology Laboratory and worked on two projects which were later published in Nature Scientific Reports and Elsevier Computational Biology and Chemistry. After a brief stint in industry, he's now pursuing his Master's at Yale.

 

Sonika Bhatnagar

Sonika Bhatnagar, Ph.D. (Biophysics), AIIMS works in the broad area of computational molecular biology. Her laboratory uses techniques of drug target selection, drug design & discovery, machine learning, and integrative genomics & proteomics towards Cardiovascular disease drug design and infectious disease therapeutics.

 

2

Six Sigma - Time, cost and product quality improvement

Ashwin Kuchekar

Ashwin Kuchekar is an Associate Professor and the Head of Career Services and Placement at the School of Pharmacy, Dr. Vishwanath Karad MIT-WPU in Pune. He completed his M. Pharm.in 2009 and Ph. D. in 2015. In 2012, he received the Senior Research Fellow (SRF) Award from the Council of Scientific Industrial and Research (CSIR).  He is a trained specialist in Lean Six Sigma Black Belt (LSSBB).  He has 7 years of industrial experience in reputed pharmaceutical companies such as Piramal, Lupin, and Abbott Healthcare. He has a unique blend of statistics and formulation development, Quality by Design with exposure to branded and generic product development. He has practical experience in the Design of Experiments and product formulation and process optimisation.

 

3

Probiotics as live Biomolecules to Manage Sleep Disorders

Sumel Ashique

Sumel Ashique, Assistant Professor at Bharat Technology, is an accomplished pharmaceutical scientist with 150+ publications, 5 patents, and expertise in drug delivery and nanotechnology. He serves as a reviewer and guest editor for reputed journals and is currently pursuing a Ph.D. at Lovely Professional University, Punjab.

Mohini Mondal

Mohini Mondal, Assistant Professor at Bharat Technology, is a dedicated pharmaceutics academic and researcher. With an M. Pharm and ongoing Ph.D., she specializes in drug delivery systems and holds an IP for an innovative ocular gel. Her work bridges teaching and research, shaping future pharmaceutical professionals.

4

Advanced Nanobots for ‘Programmed’ Biomedical Applications

Amaresh Kumar Sahoo

Assistant Professor, Department of Applied Sciences, Indian Institute of Information Technology

Saurabh Shivalkar

Research Fellow, Department of Applied Sciences, Indian Institute of Information Technology

5

Meet scientist Daria Donati

Daria Donati

Daria’s work is ongoing. Her role at Cytiva involves identifying new and innovative technologies that can help in the development of therapeutics. This means building partnerships, improving manufacturing processes and, ultimately, getting life- saving drugs to the people who need them most.

 

press releasesRead more...

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased

Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL

Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders

EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific

EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company

Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine

EventsRead more...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

03 - 05

Nov 2026

10th Dermatology Drug Development

Boston, Massachusetts at The C...

03 - 04

Nov 2026

PDA Aseptic Processing of Biopharma Conference

Sheraton Grand Incheon Hotel,...

04 - 05

Nov 2026

Advanced Therapies USA

Hynes Convention Center, Bosto...

05 - 05

Nov 2026

PDA Contamination Control Strategy Workshop

Sheraton Grand Incheon Hotel,...

09 - 11

Nov 2026

11th Microbiome Movement USA Summit

The Colonnade Hotel, Boston, M...

LATEST NEWSRead more...

Adalvo Acquires Romiplostim Biosimilar from Enzene

Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...

Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation

Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...

Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044

Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...

Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia

Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement

Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer

Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...

Okomera Signs Agreement with Servier for Cancer Research Technology

Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...